+ Site Statistics
References:
54,258,434
Abstracts:
29,560,870
PMIDs:
28,072,757
+ Search Articles
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ PDF Full Text
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Translate
+ Recently Requested

Early versus late intensification for patients with high-risk Hodgkin lymphoma-3 cycles of intensive chemotherapy plus low-dose lymph node radiation therapy versus 4 cycles of combined doxorubicin, bleomycin, vinblastine, and dacarbazine plus myeloablative chemotherapy with autologous stem cell transplantation: five-year results of a randomized trial on behalf of the GOELAMS Group



Early versus late intensification for patients with high-risk Hodgkin lymphoma-3 cycles of intensive chemotherapy plus low-dose lymph node radiation therapy versus 4 cycles of combined doxorubicin, bleomycin, vinblastine, and dacarbazine plus myeloablative chemotherapy with autologous stem cell transplantation: five-year results of a randomized trial on behalf of the GOELAMS Group



Cancer 113(12): 3323-3330



The 5-year freedom from treatment failure (FFTF) rate, with treatment failure defined as the lack of post-treatment complete remission (CR), recurrence, or death, ranges from 60% to 70% after 6 to 8 cycles of combined doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD), which is the reference treatment for patients with advanced Hodgkin lymphoma (HL). In this randomized, phase 2 study, the authors tested 2 intensive chemotherapy regimens in 158 patients with clinical stage (CS) IIB through IV HL accompanied by high-risk factors who were recruited between May 1997 and December 2004. High-risk CS IIB, III, and IV were defined by the presence of > or =5 involved lymphoid areas, and/or a mediastinal mass ratio > or =0.45, and/or > or =2 extra lymph node sites affected by the disease (for CS IV). In Arm V, 82 patients received 3 courses of combined vindesine (5 mg/m(2)), doxorubicin (99 mg/m(2)), carmustine (140 mg/m(2)), etoposide (600 mg/m(2)), and methylprednisolone (600 mg/m(2)) (VABEM) followed by low-dose lymph node irradiation. In Arm A, 76 patients received 4 cycles of ABVD followed by myeloablative combined carmustine (300 mg/m(2)), etoposide (800 mg/m(2)), cytarabine (1600 mg/m(2)), and melphalan (140 mg/m(2)) and underwent autologous stem cell transplantation. After 3 cycles of VABEM, the CR rate was 89% versus 60% after 4 cycles of ABVD. However, after the completion of treatment, the CR rates for Arms V and A were similar (89% and 88%, respectively). The 5-year FFTF rates for Arms V and A also were similar (79% and 75%, respectively) along with the 5-year overall survival rates (87% and 86%, respectively). Early intensification (Arm V) and late intensification (Arm A) were equally effective for treating patients with high-risk/advanced HL.

(PDF emailed within 0-6 h: $19.90)

Accession: 052764879

Download citation: RISBibTeXText

PMID: 18988286

DOI: 10.1002/cncr.23979


Related references

Reduced versus full doses of irradiation after 3 cycles of combined doxorubicin, bleomycin, vinblastine, and dacarbazine in early stage Hodgkin lymphomas: results of a randomized trial. Cancer 116(17): 4054-4062, 2010

High-risk Hodgkins disease ABVD chemotherapy followed by beam-conditioned autologous stem cell transplantation and focal radiotherapy versus intensive chemotherapy followed by involved field RT Two-year results of the Goelams H97-GM multicentric randomized trial. Blood 96(11 Part 1): 791a, November 16, 2000

Three cycles of adriamycin, bleomycin, vinblastine, and dacarbazine or epirubicin, bleomycin, vinblastine, and methotrexate plus extended field radiation therapy in early and intermediate Hodgkin disease 10-Year results of a randomized trial. Blood 103(1): 58-66, January 1, 2004

Frontline therapy with early intensification and autologous stem cell transplantation versus conventional chemotherapy in unselected high-risk, aggressive non-Hodgkin's lymphoma patients: a prospective randomized GEMOH report. Acta Haematologica 115(1-2): 15-21, 2006

Three cycles of adriamycin, bleomycin, vinblastine, and dacarbazine (ABVD) or epirubicin, bleomycin, vinblastine, and methotrexate (EBVM) plus extended field radiation therapy in early and intermediate Hodgkin disease: 10-year results of a randomized trial. Blood 103(1): 58-66, 2003

Very High Risk Hodgkins Disease ABVD Plus BEAM Followed by Autologous Stem Cell Transplantation and Radiotherapy Versus Intensive Chemotherapy and RT Interim Results of the GOELAMS H97-GM Multicentric Randomized Trial. Blood 100(11): Abstract No 811, November 16, 2002

Chemotherapy of hodgkin's lymphoma with alternating cycles of copp cyclophosphamide vincristine procarbazine prednisone and abvd doxorubicin bleomycin vinblastine and dacarbazine results of the hd1 and hd3 trials of the german hodgkin study group. Medical Oncology and Tumor Pharmacotherapy 6(2): 155-162, 1989

Risk-adapted therapy with three or six cycles of doxorubicin/bleomycin/vinblastine/dacarbazine plus involved-field radiation therapy in Hodgkin lymphoma, based on prognosis at diagnosis and early response: results from the GATLA study. Clinical Lymphoma, Myeloma and Leukemia 10(3): 181-185, 2010

Early autologous stem-cell transplantation versus conventional chemotherapy as front-line therapy in high-risk, aggressive non-Hodgkin's lymphoma: an Italian multicenter randomized trial. Journal of Clinical Oncology 21(7): 1255-1262, 2003

High-dose therapy followed by autologous purged stem cell transplantation and doxorubicin-based chemotherapy in patients with advanced follicular lymphoma: a randomized multicenter study by the GOELAMS with final results after a median follow-up of 9 years. Blood 113(5): 995-1001, 2008

High-dose therapy followed by autologous purged stem-cell transplantation and doxorubicin-based chemotherapy in patients with advanced follicular lymphoma: a randomized multicenter study by GOELAMS. Blood 105(10): 3817-3823, 2005

Consolidation radiation after complete remission in Hodgkin's disease following six cycles of doxorubicin, bleomycin, vinblastine, and dacarbazine chemotherapy: is there a need?. Journal of Clinical Oncology 22(1): 62-68, 2003

Chemotherapy vs radiotherapy for remission consolidation after three double cycles of cyclophosphamide vincristine procarbazine prednisone copp and doxorubicin bleomycin vinblastine dacarbazine abvd a randomized trial in patients with stages iiib iv hodgkins lymphoma. Journal of Cancer Research & Clinical Oncology 116(SUPPL PART 1): 613, 1990

High-dose therapy and autologous stem-cell transplantation versus conventional-dose consolidation/maintenance therapy as postremission therapy for adult patients with lymphoblastic lymphoma: results of a randomized trial of the European Group for Blood and Marrow Transplantation and the United Kingdom Lymphoma Group. Journal of Clinical Oncology 19(11): 2927-2936, 2001

Frontline High-Dose Chemotherapy with Autologous Stem Cell Transplantation vs Standard CHOP Regimen for Patients with Non IPI High-Risk Intermediate or High-Grade Lymphomas Final Results of a Randomized Trial by the GOELAMS. Blood 100(11): Abstract No 675, November 16, 2002